RT Journal Article
SR Electronic
T1 A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.11.10.465032
DO 10.1101/2021.11.10.465032
A1 Jelínková, Lucie
A1 Flores-Garcia, Yevel
A1 Shapiro, Sarah
A1 Roberts, Bryce T.
A1 Petrovsky, Nikolai
A1 Zavala, Fidel
A1 Chackerian, Bryce
YR 2021
UL http://biorxiv.org/content/early/2021/11/11/2021.11.10.465032.abstract
AB Pre-erythrocytic malaria vaccines that induce high-titer, durable antibody responses can potentially provide protection from infection. Here, we engineered a virus-like particle (VLP)-based vaccine targeting a recently described vulnerable epitope at the N-terminus of the central repeat region of the Plasmodium falciparum circumsporozoite protein (CSP) that is recognized by the potently inhibitory monoclonal antibody L9 and show that immunization with L9 VLPs induces strong antibody responses that provide protection from blood-stage malaria in a mouse infection model.Competing Interest StatementB.C. has equity in FL72, a company that does not have financial interest in malaria vaccines. N.P. is affiliated with Vaxine Pty Ltd, a company having a financial interest in Advax adjuvants. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.